Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘Pay-For-Delay’ Deals Likely Put On Hold Themselves After Cipro Ruling

This article was originally published in The Pink Sheet Daily

Executive Summary

California Supreme Court finds patents are ‘probablistic rather than ironclad,’ and outlines four-prong antitrust test that further complicates brand/generic deal making.

You may also be interested in...



Teva Settles 16-Year Cipro Pay-For-Delay Litigation For $225M; Will Focus Shift To Pricing Deals?

California indirect purchasers reached previous settlements with Bayer and three other firms; plaintiffs’ attorney sees shift from reverse-payment to price fixing and market swapping cases. Trump appointments to FTC could influence direction of scrutiny.

Teva Settles 16-Year Cipro Pay-For-Delay Litigation For $225M; Will Focus Shift To Pricing Deals?

California indirect purchasers reached previous settlements with Bayer and three other firms; plaintiffs’ attorney sees shift from reverse-payment to price fixing and market swapping cases. Trump appointments to FTC could influence direction of scrutiny.

Teva Pay-For-Delay Plausible; Judge Finds Payments Exceed Litigation Costs

Focused on $300 million in payments Cephalon made to generic firms to settle Provigil patent suits, case is second to proceed to trial since Supreme Court’s Actavis decision.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS078467

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel